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Background: Conventional axillary lymph node dissection (ALND) has recently become less radical. The treatment
morbidity effects of reduced ALND aggressiveness are unknown. This article investigates the prevalence of the main
complications of ALND: lymphedema, range-of-motion restriction, and arm paresthesia and pain.
Methods: This cross-sectional study included 200 women with invasive breast cancer who underwent breast-conserving
surgery (82.5%, n = 165) or mastectomy (17.5%, n = 35) with ALND from 2007 to 2011. Arm perimetry was used to assess
lymphedema, defined as a difference >2 cm in the upper arm circumference between the nonsurgical and surgical arms.
Range-of-motion restriction was assessed by evaluating the degree of arm abduction. Paresthesia was measured in the
inner and proximal arm regions. Arm pain was assessed by directly questioning the patients and defined as either present
or absent.
Results: The average (±SD) time between ALND and morbidity evaluation was 35 ± 18 months (range, 7-60 months).
The average dissected lymph node number per patient was 14 ± 4 (range, 6-30 lymph nodes). Only 3.5% (n = 7) of the
patients presented with lymphedema. Single-incision approaches to breast tumor and ALND (P = 0.04) and the presence
of a postoperative seroma (P = 0.02) were associated with lymphedema in univariate analysis. Paresthesia was the most
frequent side effect observed (53% of patients, n = 106). This complication was associated with increased age (P < 0.0001)
and a larger dissected lymph node number (P = 0.01) in univariate and multivariate analysis. Additionally, 24% (n = 48) of
patients had noticeable limited arm abduction. Among the patients, 27.5% (n = 55) experienced sporadic arm pain
corresponding to the surgically treated armpit. In multivariate analysis, the pain risk was 1.9-fold higher in patients who
underwent ALND corresponding to their dominant arm (95% CI, 1.0-3.7, P = 0.04).
Conclusion: Conventional ALND in breast cancer patients can result in unwanted complications. However, the current
lymphedema prevalence is lower than that of the other analyzed side effects.
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Axillary lymph node dissection (ALND), although contro-
versial in specific situations, remains an integral part of
surgical treatments in patients with invasive breast cancer
and axillary lymph node metastases [1]. Specifically, this
treatment is applicable in patients with tumors that are
considered N1 or N2 according to the TNM staging* Correspondence: ewss@ig.com.br
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unless otherwise stated.system [2]. ALND was replaced in clinical practice by sen-
tinel lymph node biopsy (SLNB) in patients that lack axil-
lary lymph node involvement (N0) and some N1 patients
[3], due to its reduced morbidity [4-7]. However, despite
widespread mammography use for disease screening and
early diagnosis, approximately one-third of patients in the
U.S. suffer from tumors that have spread to the regional
lymph nodes at diagnosis according to the Surveillance,
Epidemiology and End Results (SEER) database [8]. In
Brazil, according to National Department of Health statis-
tics (2012), only 18% of these cancers are confined to the
breast at diagnosis (pathologic stage), despite efforts to
provide screening mammography for all women agedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Soares et al. World Journal of Surgical Oncology 2014, 12:67 Page 2 of 8
http://www.wjso.com/content/12/1/67older than 40 years [9]. This late diagnosis means that,
proportionally, more patients are submitted to ALND in
Brazil than their American counterparts.
Currently, conventional ALND involves lymph node
resection in levels I and II, as described by Berg [10].
Such dissections serve therapeutic functions and enable
disease stage and prognosis assessments [11]. Unfortu-
nately, ALND is primarily responsible for functional surgi-
cal treatment sequelae, including lymphedema, paresthesia,
range-of-motion restriction, and pain in the arm ipsilateral
to the lymph node dissection. Although esthetic sequelae
that are caused by partial or total surgical breast resection
can be reversed or minimized by reconstructive surgery
methods that include prosthetics and tissue flaps, little can
be done to correct the functional sequelae [12].
Since Halsted advocated the ‘systematic cleaning out of
the axilla’ as an essential part of the operation ‘for the cure
of cancer of the breast’ in 1907 [13], efforts to reduce the
radicality and extent of tissue resection in ALND have
been proposed. In 1948, Patey and Dyson [14] initially pre-
served the pectoralis major muscle but resected the pec-
toralis minor muscle along with ALND. Subsequently,
Auschincloss [15] and Madden [16] proposed and closely
described ALND with preservation of the pectoralis major
and minor muscles in 1963 and 1965, respectively. The
dissection of Berg level III has ceased in recent years [17],
and the number of lymph nodes resected have decreased.
A review of 21,992 women in the California Cancer Regis-
try, who underwent ALND between 2004 and 2008, re-
vealed an average of 11.4 ± 7.4 dissected lymph nodes per
ALND [18]. In the 1960s, Auschincloss described an aver-
age of 38 lymph nodes per ALND [15]; this difference sug-
gests that ALND has become increasingly conservative.
Previous studies have shown that the incidence rates of
complications and sequelae in the arm, including lymph-
edema, are directly related to the locoregional treatment
radicality, which involves surgery and radiation therapy
[19,20]. In the 1990s, studies showed that the incidence of
lymphedema was decreasing due to more conservative ap-
proaches to the axilla [21].
Accordingly, this study aims to assess the current preva-




A cross-sectional study was performed at the Cancer Study
and Treatment Center of Western Paraná (União Oeste
Paranaense de Estudos e Combate ao Câncer, UOPEC-
CAN), a cancer patient treatment center in Cascavel city
and a principal cancer treatment center in southern Brazil.
The study was approved by the UOPECCAN Review Com-
mittee on Grant Proposals and Research Studies and the
Research Ethics Committee of the State University ofWestern Paraná. Two hundred patients who underwent
surgeries from January 2007 to December 2011 were evalu-
ated. In all cases, informed consent and data collection was
performed through specific interview and physical examin-
ation for the research.
Inclusion and exclusion criteria
Women with histologically confirmed invasive breast car-
cinoma without distant metastases (M0) at diagnosis were
included in this study. All patients underwent ALND asso-
ciated with mastectomy or breast-conserving surgery and
radiotherapy. Wherever possible, the ALND was per-
formed by the same surgical incision used to approach the
mammary tumor. When appropriate, the patients received
chemotherapy, breast radiotherapy, immunotherapy, and
hormonal blockade. No patient had the axillary nodal re-
gion included in the radiation field. The sequelae assess-
ment was performed after chemotherapy or radiation
therapy completion.
The exclusion criteria were defined as the presence of
bilateral breast cancer, other malignancies except non-
melanoma skin cancer and deformities, fractures, or
previous surgery in the upper limb ipsilateral to the
ALND. In the sequelae assessment period (July 2012 to
December 2012), 33 potential candidates missed the
study monitoring and were not located, 32 patients died
from the disease or other causes, and four patients re-
fused to participate.
Research tools
1. Lymphedema (arm swelling)
The upper arm circumference (in cm) at 15 cm
proximal to the lateral epicondyle ipsilateral to the
axilla surgery site was compared with the
contralateral upper arm circumference, just as
described by Veronesi et al. [22]. Lymphedema
was defined as a difference >2 cm in the upper
arm circumference between the arm ipsilateral to
the ALND and the non-surgical arm.
2. Paresthesia
The arm ipsilateral to the ALND was evaluated by
touch response to a cotton ball on the inside of
the arm at three points: proximal, medial, and
distal; the resultant reaction was compared to that
of the opposite arm. The patients were examined
in a sitting position with the arms outstretched at
90 degrees. The evaluation result was defined as
either present or absent (paresthesia).
3. Mobility
Rangeofmotion was evaluated by bilateral arm
abduction with a protractor, and the categories
were defined as follows: absent for 180 degrees of
abduction, mild for 120 to 179 degrees of
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abduction, and severe for abduction below
90 degrees.
4. Pain
The pain level was evaluated by directly asking the
patient about the presence or absence of any arm
pain. No pain score was used. The pain response
was recorded as present or absent.
Additional data regarding patient characteristics, tumor
stage, and treatment performed were obtained from med-
ical records.
Statistical analysis
The means and standard deviation (±) were used to assess
numerical values. The associations between the variables
studied (lymphedema, paresthesia, range-of-motion re-
striction, and pain) and the other patient characteristics
were assessed using Fisher’s exact test for the binary nom-
inal variables and the Mann-Whitney test for continuous
numeric variables. Multivariate analysis was performed
using multiple logistic regression tests for the binary vari-
ables and multiple linear regression tests for the continu-
ous variables. A Pvalue <0.05 was considered significant.
The data were analyzed using the BioEstat® software statis-
tical package, version 5.3(available at, http://www.mamir-
aua.org.br/).
Results
The mean interval between ALND and analysis was
35 months (standard deviation, 18 months) with a range of
7 to 60 months. The average dissected lymph node number
per patient was 14 ± 4 (range, 6-30 lymph nodes). None of
the patients exhibited axillary recurrence during the ana-
lysis period. The patient and treatment characteristics are
shown in Table 1.
Lymphedema was the least frequent complication and
was found in only 3.5% (n = 7) of patients. Paresthesia was
the most frequent complication and was observed in 53%
(n = 106) of patients. Arm range-of-motion restriction,
which was observed in 24% (n = 48) of the patients, and
pain, which was reported by 27.5% (n = 55) of the inter-
viewed patients, occurred with moderate frequency. Be-
cause 95% (n = 190) of the evaluated patients received
breast radiotherapy and 96% (n = 192) received some type
of chemotherapy to treat their breast cancer, both of these
treatment modalities were excluded as potential variables
from statistical analysis.
Lymphedema
The low case number in this study precluded the multi-
variate analysis of lymphedema with the other variables.
Associations between the presence of lymphedema with
single-incision breast surgery (breast-conserving surgeryor mastectomy) and ALND (P = 0.04) or with the pres-
ence of postoperative seroma (P = 0.02) were found via
univariate analysis (Table 2).
Paresthesia
Paresthesia, the most frequent side effect of ALND, oc-
curred mainly in older patients and in ALND patients with
the most dissected nodes (Table 3). This association was
observed in both the univariate and multivariate analyses.
The average age of patients with paresthesia was 58 ±
11 years versus 49 ± 10 years for the group without
paresthesia (P < 0.0001). On average, 15 ± 4 lymph nodes
were dissected in the group with paresthesia versus 13 ± 4
lymph nodes in the group without paresthesia (P = 0.002).
Range-of-motion restriction
Although range-of-motion restriction, as assessed by the
degree of abduction of the arm ipsilateral to ALND, was
found in 24% (n = 48) of patients, it was considered mild
in 15% (n = 30), moderate in 8% (n = 16), and severe in
only 1% (n = 2) of patients. The univariate analysis re-
vealed an association between the range-of-motion restric-
tion with single-incision breast surgery (breast-conserving
surgery or mastectomy) and ALND (P = 0.02, Table 4).
However, this association was not confirmed by the multi-
variate analysis.
Pain
Sporadic pain in the arm ipsilateral to the ALND, which
was present in 27.5% (n = 55) of the evaluated patients,
did not associate with the other variables in a univariate
analysis. However, the pain risk was 1.9-fold higher in
patients who underwent ALND ipsilateral to the domin-
ant arm (95% CI, 1.0-3.7; P = 0.04), according to the
multivariate analysis (Table 5).Discussion
ALND’s importance in the staging, prognostic assess-
ment and local control of breast cancer has long been
proven [23]. Local control of breast cancer also results
in longer survival [24], and failing to ‘clean’ the axilla
could mean a loss of disease control with distant metas-
tases, such as that noted in the NSABP B-04 study [25].
If not for the morbidity, the need for ALND would not
be debated in cases of SLNB positivity [3]. In contrast,
the incorporation of SLNB in breast cancer treatment
has benefited many women with the disease at an early
stage, confined to the breast, avoiding ALND. This treat-
ment course substantially decreased functional sequelae
risks in the arm that result from surgical armpit manipu-
lation. Because women are increasingly surviving breast
cancer [26], ALND morbidity is generating a high social,
psychological, and financial cost.
Table 1 Clinical characteristics and treatments of the 200
patients in the study
Characteristic Number of patients (%)
Age (years)






Surgery - evaluation interval















Surgery in the dominant arm
Yes 94 (47)
No 106 (53)
Incision for axillary dissection
The same as the breast’s 122 (61)
Separate 78 (39)
Status of lymph nodes
At least one metastatic 103 (51.5)
Absence of metastases 97 (48.5)
Lymph nodes with metastases (103)
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present with stage III and IV disease at diagnosis [9]. In
this study, 51.5% of the patients (n = 103) had metastases
in the axillary lymph nodes. The N0 patients who under-
went ALND (48.5%, n = 97) had contraindications to
SLNB (for example, inflammatory breast cancer, T4 tu-
mors, clinically positive axilla) or refused the procedure.
Currently, conservative surgery combined with breast
radiation therapy is considered as effective as total mast-
ectomy for the local control of breast cancer [27,28].
This combination treatment was administered to 82.5%
(n = 165) of the patients in this study. Previous studiesTable 2 Relationships between lymphedema and the
other variables
Patient subgroups Lymphedema P valuea
Yes (%) No (%)
Mean age (years) 54 ± 12 53 ± 11 0.82
Surgery - evaluation interval (months) 34 ± 24 35 ± 17 0.84
Surgery 0.1
Mastectomy 3 32 (16.5)
Conservative surgery 4 161 (83.5)
ALND incision 0.04
The same as the breast’s 7 115 (59.5)
Separate 0 78 (40.5)
Axilla status 0.11
Positive 6 97 (50.2)
Negative 1 96 (49.8)
Surgery in the dominant arm 0.25
Yes 5 89 (46.1)
No 2 104 (53.9)
Positive axilla (103): number
of positive lymph nodes
9 ± 10 5 ± 4 0.2
Dissected lymph nodes 16 ± 6 14 ± 4 0.36
Postoperative seroma 0.02
Yes 3 17 (8.8)
No 4 176 (91.2)
aFisher’s exact test for binary nominal variables and the Mann-Whitney test for
continuous numeric variables.
ALND: axillary lymph node dissection.
Table 3 Relationships between paresthesia and the other
variables
Patient subgroups Paresthesia P valuea
Yes No
Mean age (years) 58 ± 11 49 ± 10 <0.0001
Surgery -evaluation interval (months) 34 ± 18 36 ± 18 0.32
Surgery 1
Mastectomy 19 (17.9) 16 (17)
Conservative surgery 87 (82.1) 78 (83)
ALND incision 0.56
The same as the breast’s 67 (63.2) 55 (58.5)
Separate 39 (36.8) 39 (41.5)
Surgery in the dominant arm 1
Yes 50 (47.2) 44 (46.8)
No 56 (52.8) 50 (53.2)
Axilla status 0.25
Positive 59 (55.7) 44 (46.8)
Negative 47 (44.3) 50 (53.2)
Positive axilla (103): number
of positive lymph nodes
3 ± 5 4 ± 5 0.17
Dissected lymph nodes 15 ± 4 13 ± 4 0.002
Postoperative seroma 0.63
Yes 12 (11.3) 8 (8.5)
No 94 (88.7) 86 (91.5)
aFisher’s exact test for binary nominal variables and the Mann-Whitney test for
continuous numeric variables.
ALND: axillary lymph node dissection.
Table 4 Relationships between range-of-motion restriction





Mean age (years) 54 ± 12 53 ± 11 0.96
Surgery -evaluation interval (months) 35 ± 20 35 ± 17 0.75
Surgery 0.12
Mastectomy 12 (25) 23 (15.1)
Conservative surgery 36 (75) 129 (84.9)
ALND incision 0.02
The same as the breast’s 36 (75) 86 (56.6)
Separate 12 (25) 66 (43.4)
Surgery in the dominant arm 0.6
Yes 24 (50) 70 (46.1)
No 24 (50) 82 (53.9)
Axilla status 0.74
Positive 26 (54.2) 77 (50.6)
Negative 22 (45.8) 75 (49.4)
Positive axilla (103): number
of positive lymph nodes
7 ± 6 4 ± 4 0.1
Dissected lymph nodes 14 ± 5 14 ± 4 0.89
Postoperative seroma 0.78
Yes 4 (8.3) 16 (10.5)
No 44 (91.7) 136 (89.5)
aFisher’s exact test for binary nominal variables and the Mann-Whitney test for
continuous numeric variables.
ALND: axillary lymph node dissection.
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the morbidity prevalence. Schünemann and Willich [19]
evaluated 5,868 patients with breast cancer treated from
1972 to 1995 and demonstrated that the addition of
radiotherapy to modified radical mastectomy increased
the lymphedema incidence from 19.1% to 28.9%. DiSipio
et al. [20], in a systematic review and meta-analysis that
evaluated 72 studies, associated chemotherapy with lymph-
edema. These two variables (radiotherapy and chemother-
apy) were not evaluated in this study, because the vast
majority of the patient cohort (95% and 96% respectively)
was subjected to these therapeutic modalities.
Lymphedema is by far the most serious and difficult to
treat complication that has the greatest effect on a pa-
tient’s quality of life. However, lymphedema is not the
only ALND-related complication. The literature primar-
ily reports lymphedema, paresthesia, pain, and range-
of-motion restriction as complications of ALND. The
risk of complications correlates positively with the
radical nature of ALND [19,29].
The lymphedema incidence and prevalence described in
the literature vary widely, possibly due to different meas-
urement methods and intervals between ALND andlymphedema measurement. DiSipio et al. [20] observed a
21.4% lymphedema incidence after analyzing 30 prospect-
ive cohort studies. Therefore, the 3.5% prevalence ob-
served in this study is below the literature average. The
lymphedema measurement method used in this study (cir-
cumference measurement) is simple, easily reproducible,
and the most used approach in the medical literature.
Using this method, the average lymphedema incidence
observed was 14.8%, as described by DiSipio et al. [20]
Another study using the same lymphedema assessment
criteria (upper limb measurement difference of >2 cm be-
tween the arms) was conducted in Greece by Keramopou-
los et al. [30] and reported a 17% lymphedema incidence.
Possible explanations for this unexpectedly low lymph-
edema prevalence are the lack of systematic dissection of
level III, the lack of interpectoral space exploration (Rotter
lymph nodes), and the attempted preservation of the pec-
toral muscles. Evidently, this approach results in fewer dis-
sected lymph nodes, as noted in the present study with an
average of 14 dissected lymph nodes per patient. However,
none of the patients showed axillary recurrence during
the analysis period. Although this number is lower than
the 38 dissected lymph nodes per patient reported in the
Table 5 Relationships between pain and the other variables
Variables Odds ratio 95% CI P-valuea
Mean age (52 years vs. 54 years)b 0.16
Surgery – Evaluation. interval (34 vs. 36 months)b 0.41
Surgery (mastectomyvs. conservative breast surgery) 1.4 0.6-3.5 0.38
Incision (single vs. separate) 0.9 0.4-2.0 0.95
Surgery (dominant arm vs. non-dominant arm.) 1.9 1.0-3.7 0.04
Axilla status (positive vs. negative) 1.3 0.7-2.6 0.37
Number of positive lymph nodes (6 vs. 5)b 0.24
Number of dissected lymph nodes (14 vs. 14)b 0.65
Postoperative seroma (yes vs. no) 0.7 0.2-2.3 0.65
aMultivariate analysis: multiple logistic regression tests for binary variables and multiple linear regression for continuous variables.
bMultiple linear regression for continuous variables does not generate odds ratio and CI.
CI: confidence interval.
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rently considered to be an adequate minimum number
[31,32]. It is also important to note that the time be-
tween ALND and analysis was less than 2 years in some
patients. The review conducted by DiSipio et al. [20]
demonstrated that lymphedema appears to increase
2 years after diagnosis of or surgery for breast cancer.
The fact that no patient had the axillary nodal region in-
cluded in the radiation field may also have contributed
to reduce the risk of lymphedema.
Finally, another important aspect to be considered is
that difference of >2 cm between the arms may be too
much to objectively evaluate lymphedema morbidity and
an investigation with upper limb lymphoscintigraphy, for
example, would have helped to detect lymphatic impair-
ment much earlier than clinically. Therefore, this may
have led to an underestimation of lymphedema prevalence
in our results.
Paresthesia was the most frequent complication in
this study and was found in more than half of the pa-
tients (53%, n = 106). Veronesi and colleagues [22]
reported a prevalence of 68%, and Warmuth et al. [12]
reported a prevalence of 35%. This finding is related to the
intercostobrachial nerve section that crosses the axilla and
is transected during ALND. However, paresthesia is a
minor complication that neither results in complaints nor
limits the quality of life in most cases [33]. There was no
intent to preserve the intercostobrachial nerve (ICBN)
during ALND for the patients evaluated in the present
study.
Pain and range-of-motion restriction occurred in 27.5%
(n = 55) and 24% (n = 48) of the patients, respectively. The
range-of-motion restriction was evaluated according to
the degree of arm abduction, a method that has been pre-
viously used [34]. The pain and range-of-motion restric-
tion incidence rates vary widely in literature reports.
Warmuth et al. [12] identified an 8% limitation in arm
movement and a 30% incidence of pain in 432 patients 2to 5 years after ALND. Kootstra et al. [35] evaluated 76
women and observed that 70% had clinical relevant im-
pairments in the shoulder and arm 7 years after ALND. It
is noteworthy that 62.5% (n = 30) of patients who pre-
sented with range-of-motion restriction (n = 48) had only
mild range-of-motion restriction (120° to 179° abduction).
The range-of-motion restriction might be overestimated
in the present study because a rangeofmotion of at least
160° can be considered normal [36].
This study also found a correlation between lymph-
edema and single-incision surgery. This fact was not ad-
dressed in related previous studies. A possible explanation
is that in breast-conserving surgery, attempts to approach
the breast (quadrantectomy) and axilla (ALND) through
the same incision sometimes create tunnels that compli-
cate the correct identification of planes that involve the
axilla and the preservation of the periaxillary subcutane-
ous tissue.
The present study also found an association between
paresthesia and advanced patient age. Ververs and col-
leagues reported an opposite finding [37]. They discovered
an inverse relationship between arm paresthesia and pa-
tient age.
The present study showed that pain, a subjective datum,
was associated with surgery ipsilateral to the dominant
arm. This association was also found in a previous study
by Hayes and colleagues [38].Conclusion
In conclusion, although SLNB has benefited many
women with breast cancer, many patients still require
ALND, despite its associated risk for morbidity. The re-
sults of this study showed that the lymphedema preva-
lence, the most undesirable ALND side effect, was low
in relation to other evaluated symptoms. Further, larger
prospective studies are required to fully assess the exact
morbidity incidence following ALND.
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